NanoString Technologies' increasingly diverse portfolio of molecular analysis products is set to expand in coming quarters.

On a recent earnings call, executives at the Seattle-based company discussed a number of internal R&D initiatives that are expected to yield new products, among them a benchtop version of its nCounter Analysis system, as well as multianalyte and protein analysis assays.

They also provided an update on the launch of NanoString's Elements general purpose reagents and the company's Prosigna Breast Cancer Assay.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.